Clinical Trials Logo
  1. Home
  2. Hyponatremia
  3. NCT00379847
  4. Details
NCT00379847 Clinical Trial

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia Clinical Trial

Official title:
A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00379847
Other study ID # 087-CL-080
Secondary ID
Status Completed
Phase Phase 3
First received September 21, 2006
Last updated April 30, 2014
Start date February 2004
Est. completion date June 2005

Study information
Verified date April 2014
Source Cumberland Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationIsrael: Israeli Health Ministry Pharmaceutical AdministrationSouth Africa: Medicines Control Council
Study type Interventional

Clinical Trial Summary

This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.

Recruitment information / eligibility
Status Completed
Enrollment 251
Est. completion date June 2005
Est. primary completion date June 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Serum sodium levels less than or equal 130mEq/L

- Euvolemic or Hypervolemic hyponatremia

Exclusion Criteria:

- Clinical evidence of volume depletion or dehydration

- Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency

- Uncontrolled brady-or tachyarrhythmias requiring pacemaker placement or treatment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• conivaptan
IV

Locations
Country Name City State
Israel 2 Sites Haifa
Israel 2 Sites Jerusalem
Israel 2 Sites Safed
South Africa 2 Sites Durban
South Africa 4 Sites Johannesburg

Sponsors (1)
Lead Sponsor Collaborator
Cumberland Pharmaceuticals

Countries where clinical trial is conducted

United States,  Israel,  South Africa, 

Outcome
Type Measure Description Time frame Safety issue
Primary Baseline-adjusted change in AUC for serum sodium 96 Hours No
Secondary Comparison of safety between patients in each study arm 96 Hours No
See also
  Status Clinical Trial Phase
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Recruiting NCT04561531 - Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia. N/A
Terminated NCT02012959 - Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia Phase 3
Recruiting NCT02936167 - Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children N/A
Completed NCT00621348 - Maintenance Intravenous Fluids in Children Phase 3
Terminated NCT03703713 - Colloid Osmotic Pressure and Osmolality in Hyponatremia
Completed NCT02926989 - Intravenous Fluids in Hospitalised Children Phase 4
Terminated NCT02959411 - Tolvaptan for Advanced or Refractory Heart Failure Phase 4
Completed NCT02573077 - An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Withdrawn NCT02667977 - Reexamining Hypotonic Intravenous Fluid Use N/A
Terminated NCT01708811 - Hyponatremia and Myometrium Contractility. An Invitro Study N/A
Withdrawn NCT01326429 - Frequency and Origin of Dysnatremias in the Emergency Department N/A
Completed NCT01456533 - Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients N/A
Terminated NCT01227512 - Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Phase 3
Recruiting NCT06013800 - Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
Terminated NCT04020926 - Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function
Withdrawn NCT02442674 - A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia Phase 3
Completed NCT02545101 - An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH N/A
Terminated NCT02215148 - Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients N/A
Recruiting NCT01748331 - The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia N/A